Business Description
Teva Pharmaceutical Industries Ltd
NAICS : 325412
ISIN : US8816242098
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.17 | |||||
Debt-to-Equity | 2.74 | |||||
Debt-to-EBITDA | 15.26 | |||||
Interest Coverage | 3.26 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 0.2 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.4 | |||||
3-Year EPS without NRI Growth Rate | -0.1 | |||||
3-Year FCF Growth Rate | 8.9 | |||||
3-Year Book Growth Rate | -9.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 1 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 90 | |||||
9-Day RSI | 82.77 | |||||
14-Day RSI | 76.73 | |||||
6-1 Month Momentum % | 56.71 | |||||
12-1 Month Momentum % | 55.57 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.89 | |||||
Quick Ratio | 0.61 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 180.92 | |||||
Days Sales Outstanding | 78.57 | |||||
Days Payable | 109.1 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.7 | |||||
Shareholder Yield % | 7.38 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 48.95 | |||||
Operating Margin % | 20.79 | |||||
Net Margin % | -3.08 | |||||
FCF Margin % | 5.43 | |||||
ROE % | -6.73 | |||||
ROA % | -1.15 | |||||
ROIC % | 8.37 | |||||
ROC (Joel Greenblatt) % | 3.05 | |||||
ROCE % | 0.6 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 5.43 | |||||
PE Ratio without NRI | 5.96 | |||||
PS Ratio | 1.11 | |||||
PB Ratio | 2.45 | |||||
Price-to-Free-Cash-Flow | 20.01 | |||||
Price-to-Operating-Cash-Flow | 12.69 | |||||
EV-to-EBIT | 186.34 | |||||
EV-to-Forward-EBIT | 40.96 | |||||
EV-to-EBITDA | 26.52 | |||||
EV-to-Forward-EBITDA | 10.52 | |||||
EV-to-Revenue | 2.17 | |||||
EV-to-Forward-Revenue | 2.18 | |||||
EV-to-FCF | 39.48 | |||||
Price-to-Projected-FCF | 1.39 | |||||
Price-to-Median-PS-Value | 1.44 | |||||
Earnings Yield (Greenblatt) % | 0.54 | |||||
FCF Yield % | 4.92 | |||||
Forward Rate of Return (Yacktman) % | 17.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Teva Pharmaceutical Industries Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 14,786.47 | ||
EPS (TTM) (€) | -0.379 | ||
Beta | 1.06 | ||
Volatility % | 36.72 | ||
14-Day RSI | 76.73 | ||
14-Day ATR (€) | 0.281783 | ||
20-Day SMA (€) | 12.79 | ||
12-1 Month Momentum % | 55.57 | ||
52-Week Range (€) | 6.68 - 14.9 | ||
Shares Outstanding (Mil) | 1,132.64 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Teva Pharmaceutical Industries Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Teva Pharmaceutical Industries Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Teva Pharmaceutical Industries Ltd Frequently Asked Questions
What is Teva Pharmaceutical Industries Ltd(HAM:TEV)'s stock price today?
When is next earnings date of Teva Pharmaceutical Industries Ltd(HAM:TEV)?
Does Teva Pharmaceutical Industries Ltd(HAM:TEV) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |